Cardinal Health reported financial results for the first quarter of fiscal year 2014:
- Revenue decreased 5% to $24.5 billion due to contract expirations, but was partially offset by new customer growth.
- Operating earnings increased 3% to $471 million and the operating margin expanded to 1.92%.
- Non-GAAP earnings from continuing operations increased 35% to $378 million and diluted EPS increased 36% to $1.10.
- The Pharmaceutical segment saw a 7% decline in revenue but an 8% increase in segment profit. The Medical segment reported a 13% revenue increase and 43% growth in segment profit.
- For fiscal year 2014, Cardinal updated its non-GA
Staying Relevant in a High Volume, Commoditized, Medical Device Product Line ...marcus evans Network
Beth Krenzer, Cardinal Health - Speaker at the marcus evans Medical Device Manufacturing Summit Spring 2012, held in Las Vegas, NV, delivered his presentation entitled Staying Relevant in a High Volume, Commoditized, Medical Device Product Line in Manufacturing (Insourced and Outsourced)
iHT² Health IT Summit New York - Mark MacNaughton, SVP & CIO, Medial Segment at Cardinal Health - Keynote Presentation “Information as an Asset - Moving From the T Side of IT to the I”
Staying Relevant in a High Volume, Commoditized, Medical Device Product Line ...marcus evans Network
Beth Krenzer, Cardinal Health - Speaker at the marcus evans Medical Device Manufacturing Summit Spring 2012, held in Las Vegas, NV, delivered his presentation entitled Staying Relevant in a High Volume, Commoditized, Medical Device Product Line in Manufacturing (Insourced and Outsourced)
iHT² Health IT Summit New York - Mark MacNaughton, SVP & CIO, Medial Segment at Cardinal Health - Keynote Presentation “Information as an Asset - Moving From the T Side of IT to the I”
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
13. Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
(in millions, except per common share amounts)
GAAP
Restructuring and employee severance
Amortization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation (recoveries)/charges, net
Non-GAAP
GAAP
Restructuring and employee severance
Amortization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation (recoveries)/charges, net
Non-GAAP
Operating Earnings Before
Earnings
Incom e Taxes
Operating Grow th and Discontinued
Earnings
Rate
Operations
$
471
3% $
442
11
11
49
49
1
1
$
532
13 % $
503
$
$
457
5
28
1
(22)
469
11 % $
6% $
First Quarter 2014
Provision Earnings Earnings from
for
from
Continuing
Incom e Continuing Operations
Taxes
Operations Grow th Rate
$
102 $
340
25 %
4
7
18
31
1
$
124 $
378
35 %
439 $
5
28
1
(22)
451 $
The sum of the components may not equal the total due to rounding.
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
First Quarter 2013
167 $
272
2
3
10
18
1
(9)
(13)
170 $
281
Diluted EPS
Diluted EPS
from
from Continuing
Continuing
Operations
Operations
Grow th Rate
$
0.99
25 %
0.02
0.09
$
1.10
36 %
15 % $
9% $
0.79
0.01
0.05
(0.04)
0.81
16 %
11 %
14. Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
First Quarter
(in millions)
GAAP return on equity
Non-GAAP return on equity
Net earnings
Restructuring and employee severance, net of tax, in continuing operations
Amortization and other acquisition-related costs, net of tax, in continuing operations
Impairments and loss on disposal of assets, net of tax, in continuing operations
Litigation (recoveries)/charges, net, net of tax, in continuing operations
Adjusted net earnings
Annualized
Total shareholders' equity
Divided by average shareholders' equity
Non-GAAP return on equity
2013
17.3 %
2014
22.1 %
$
$
$
$
$
$
339
7
31
1
378
1,512
First
Quarter
2014
6,297
6,136
24.7 %
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
$
$
$
Fourth
Quarter
2013
5,975
$
$
271
3
18
1
(13)
280
1,120
First
Quarter
2013
6,281
6,263
17.9 %
$
Fourth
Quarter
2012
6,244
15. Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
First Quarter
(in millions)
GAAP effective tax rate from continuing operations 1
Non-GAAP effective tax rate from continuing operations
Earnings before income taxes and discontinued operations
Restructuring and employee severance
Amortization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation (recoveries)/charges, net
Adjusted earnings before income taxes and discontinued operations
Provision for income taxes
Restructuring and employee severance tax benefit
Amortization and other acquisition-related costs tax benefit
Impairments and loss on disposal of assets tax benefit
Litigation (recoveries)/charges, net tax expense
Adjusted provision for income taxes
2013
38.1 %
2014
23.2 %
$
442
11
49
1
503
$
$
102
4
18
124
$
Non-GAAP effective tax rate from continuing operations 1
$
439
5
28
1
(22)
451
$
$
167
2
10
(9)
170
$
37.8 %
24.7 %
First Quarter
2013
2014
Debt to total capital
Net debt to capital
Current portion of long-term obligations and other short-term borrow ings
Long-term obligations, less current portion
Debt
Cash and equivalents
Net debt
Total shareholders' equity
Capital
Net debt to capital
1
31 %
38 %
$
$
$
$
190
3,693
3,883
(2,753)
1,130
6,297
7,427
15 %
$
$
$
$
471
2,408
2,879
(2,440)
439
6,281
6,720
7%
The settlement of federal and state tax controversies favorably impacted, for fiscal 2014 first quarter, both the effective tax rate from continuing operations and nonGAAP effective tax rate from continuing operations by 14.3 and 12.6 percentage points, respectively. The fiscal 2014 first quarter non-GAAP effective tax rate from
continuing operations, excluding the impact of the tax settlement, w ould have been 37.3%.
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
16. Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
Fiscal Year
2013
62.3 %
(in millions)
GAAP effective tax rate from continuing operations 1
Non-GAAP effective tax rate from continuing operations
Earnings/(loss) before income taxes and discontinued operations
Restructuring and employee severance
Amorization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation (recoveries)/charges, net
Adjusted earnings before income taxes and discontinued operations
Provision for income taxes
Restructuring and employee severance tax benefit
Amortization and other acquisition-related costs tax benefit
Impairments and loss on disposal of assets tax benefit
Litigation (recoveries)/charges, net tax expense
Adjusted provision for income taxes
Non-GAAP effective tax rate from continuing operations 1
$
$
$
$
888
71
158
859
(38)
1,938
553
27
52
37
(15)
654
33.7 %
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
1
For fiscal 2013, the revaluation of the deferred tax liability and related interest on unrepatriated foreign earnings as a result of an agreement
w ith tax authorities reduced, for fiscal 2013, both the effective tax rate from continuing operations and non-GAAP effective tax rate from
continuing operations by 7.2 and 3.3 percentage points, respectively. The fiscal 2013 non-GAAP effective tax rate from continuing operations,
excluding the impact of the tax settlement, w ould have been 37.0%.
17. Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
First Quarter
(in millions)
Distribution, selling, general and administrative expenses
Restructuring and employee severance
Amortization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation (recoveries)/charges, net
Total GAAP operating expenses
GAAP operating expense grow th rate
Restructuring and employee severance
Amortization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation recoveries/(charges), net
Total Non-GAAP operating expenses
Non-GAAP operating expense grow th rate
2013
2014
$
$
$
732
11
49
1
793
13.0 %
(11)
(49)
(1)
732
6.1 %
$
$
690
5
28
1
(22)
702
$
(5)
(28)
(1)
22
690
18. Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
First Quarter
(in millions)
2013
2014
Revenue
$
24,523
$
GAAP operating earnings
Restructuring and employee severance
Amortization and other acquisition-related costs
Impairments and loss on disposal of assets
Litigation (recoveries)/charges, net
Non-GAAP operating earnings
$
471
11
49
1
532
$
GAAP operating earnings m argin rate
Non-GAAP operating earnings m argin rate
$
1.92 %
2.17 %
36bp
$
25,889
457
5
28
1
(22)
469
1.76 %
1.81 %
The sum of the components may not equal the total due to rounding.
Forw ard-Looking Non-GAAP Financial Measures
We present non-GAAP earnings from continuing operations and non-GAAP effective tax rate from continuing operations (and presentations derived from these
financial measures, including per share calculations) on a forw ard-looking basis. The most directly comparable forw ard-looking GAAP measures are earnings from
continuing operations and effective tax rate from continuing operations. We are unable to provide a quantitative reconciliation of these forw ard-looking non-GAAP
measures to the most directly comparable forw ard-looking GAAP measures because w e cannot reliably forecast restructuring and employee severance, amortization
and other acquisition-related costs, impairments and loss on disposal of assets and litigation (recoveries)/charges, net, w hich are difficult to predict and estimate and
are primarily dependent on future events. Please note that the unavailable reconciling items could significantly impact our future financial results.
19. Cardinal Health, Inc. and Subsidiaries
Schedule of Notable Item s
First Quarter
(in millions, except per common share amounts)
Restructuring and employee severance
Tax benefit
Restructuring and em ployee severance, net of tax
2013
2014
$
$
(11)
4
(7)
$
(5)
2
(3)
$
(0.02)
$
(0.01)
$
$
$
(45)
17
(28)
$
(21)
8
(13)
$
(0.08)
$
(0.04)
$
(3)
$
(7)
$
1
(2)
$
2
(5)
Decrease to diluted EPS from continuing operations
$
(0.01)
$
(0.01)
Total amortization and other acquisition-related costs 1
$
(49)
$
(28)
$
Decrease to diluted EPS from continuing operations
Am ortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets
Tax benefit
Am ortization of acquisition-related intangible assets, net of tax
Decrease to diluted EPS from continuing operations
Other acquisition-related costs
Tax benefit
Other acquisition-related costs, net of tax
Tax benefit1
10
18
1
$
(31)
$
(18)
$
(0.09)
$
(0.05)
$
$
-
$
(1)
(1)
Decrease to diluted EPS from continuing operations
$
-
$
-
Litigation recoveries/(charges), net
Tax expense
Litigation recoveries/(charges), net, net of tax
$
$
$
(1)
(1)
22
(9)
13
Increase to diluted EPS from continuing operations
$
-
$
Total am ortization and other acquisition-related costs, net of tax
Decrease to diluted EPS from continuing operations 1
Impairments and loss on disposal of assets
Tax benefit
Im pairm ents and loss on disposal of assets, net of tax
Weighted-average num ber of diluted shares outstanding
1
The sum of the components may not equal the total due to rounding.
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
$
344
$
0.04
344
20. Cardinal Health, Inc. and Subsidiaries
Asset Managem ent Analysis
First Quarter
2013
2014
Debt to total capital
Net debt to capital
38 %
15 %
22.1 %
24.7 %
Effective tax rate from continuing operations 1
Non-GAAP effective tax rate from continuing
1
operations 1
17.3 %
17.9 %
23.2 %
Return on equity
Non-GAAP return on equity
31 %
7%
38.1 %
24.7 %
37.8 %
The settlement of federal and state tax controversies favorably impacted, for fiscal 2014 first quarter, both the effective tax rate from continuing operations and nonGAAP effective tax rate from continuing operations by 14.3 and 12.6 percentage points, respectively. The fiscal 2014 first quarter non-GAAP effective tax rate from
continuing operations, excluding the impact of the tax settlement, w ould have been 37.3%.
Refer to the GAAP/Non-GAAP reconciliation for definitions and calculations supporting the Non-GAAP balances.
Given the expiration of our pharmaceutical distribution contract w ith Walgreen Co. on August 31, 2013, w e do not believe that days sales outstanding, days inventory
on hand, days payable outstanding and net w orking capital days provide meaningful measures of our w orking capital performance in fiscal 2014 first quarter.
21. Cardinal Health, Inc. and Subsidiaries
Definitions
Debt: long-term obligations plus short-term borrow ings.
Debt to Total Capital: debt divided by (debt plus total shareholders’ equity).
Interest and Other, net: other (income)/expense, net plus interest expense, net.
Net Debt: a Non-GAAP measure defined as debt minus (cash and equivalents).
Net Debt to Capital: a Non-GAAP measure defined as net debt divided by (net debt plus total shareholders’ equity).
Non-GAAP Diluted EPS from Continuing Operations: non-GAAP earnings from continuing operations divided by diluted w eighted-average shares outstanding.
Non-GAAP Earnings from Continuing Operations: earnings from continuing operations excluding (1) restructuring and employee severance1, (2) amortization and other
acquisition-related costs 2, (3) impairments and loss on disposal of assets 3 and (4) litigation (recoveries)/charges, net4, each net of tax.
Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for (1) restructuring and employee severance, (2) amortization and other
acquisition-related costs, (3) impairments and loss on disposal of assets and (4) litigation (recoveries)/charges, net) divided by (earnings before income taxes and discontinued
operations adjusted for the same four items).
Non-GAAP Operating Earnings: operating earnings excluding (1) restructuring and employee severance, (2) amortization and other acquisition-related costs, (3) impairments
and loss on disposal of assets and (4) litigation (recoveries)/charges, net.
Non-GAAP Operating Earnings Margin Rate: current period non-GAAP operating earnings divided by revenue.
Non-GAAP Operating Expenses: operating expenses excluding (1) restructuring and employee severance, (2) amortization and other acquisition-related costs, (3)
impairments and loss on disposal of assets and (4) litigation (recoveries)/charges, net.
Non-GAAP Return on Equity: (annualized net earnings excluding (1) restructuring and employee severance, (2) amortization and other acquisition-related costs, (3)
impairments and loss on disposal of assets and (4) litigation (recoveries)/charges, net, each net of tax) and divided by average shareholders’ equity.
Return on Equity: annualized net earnings divided by average shareholders’ equity.
Revenue Mix: segment revenue divided by total segment revenue for all segments.
Segm ent Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses).
Segm ent Profit Margin: segment profit divided by segment revenue.
Segm ent Profit Mix: segment profit divided by total segment profit for all segments.
1
Programs w hereby Cardinal Health fundamentally changes its operations such as closing and consolidating facilities, moving manufacturing of a product to another location,
production or business process sourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including
substantial realignment of the management structure of a business unit in response to changing market conditions).
2
Costs that consist primarily of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration
obligations.
3
Asset impairments and losses from the disposal of assets not eligible to be classified as discontinued operations are classified w ithin impairments and loss on disposal of
assets w ithin the condensed consolidated statements of earnings.
4
Loss contingencies related to litigation and regulatory matters and income from favorable resolution of legal matters.